Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 2 · newest first

  1. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched studyBlood Cancer Journal · 2025
  2. Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challengesCancer · 2025
  3. Chronic Myeloid LeukemiaJAMA · 2025
  4. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemiaCancer · 2025
  5. Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemiaCancer · 2025
  6. Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary TherapiesAmerican Journal of Hematology · 2025
  7. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationBlood Advances · 2025
  8. Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacyLeukemia & lymphoma/Leukemia and lymphoma · 2025
  9. Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic LeukemiaClinical Lymphoma Myeloma & Leukemia · 2025
  10. Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic LeukemiaAmerican Journal of Hematology · 2025
  11. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic DesignationAmerican Journal of Hematology · 2024
  12. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsHaematologica · 2024
  13. Acute myeloid leukemia management and research in 2025CA A Cancer Journal for Clinicians · 2024
  14. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapyBlood Advances · 2024
  15. Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettesLeukemia & lymphoma/Leukemia and lymphoma · 2024
  16. Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaCancer · 2024
  17. Venetoclax-Based Combination Regimens in Acute Myeloid LeukemiaBlood Cancer Discovery · 2024
  18. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabBlood Cancer Journal · 2024
  19. Incidence, Characteristics, and Outcomes of Patients with Newly Diagnosed, De Novo KIT -Mutated Non-Core Binding Factor Acute Myeloid Leukemia without Systemic MastocytosisBlood · 2024
  20. Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 AlterationsBlood · 2024
  21. Current status and research directions in acute myeloid leukemiaSHILAP Revista de lepidopterología · 2024
  22. Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies2024
  23. Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies2024
  24. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international communityLeukemia · 2024
  25. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicinBlood Cancer Journal · 2024
  26. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directionsCancer · 2024
  27. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2024
  28. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLJournal of Clinical Oncology · 2024
  29. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemiaAmerican Journal of Hematology · 2024
  30. Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisJCO Oncology Practice · 2024
  31. NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageCancer · 2024
  32. Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimensLeukemia & lymphoma/Leukemia and lymphoma · 2024
  33. FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.Journal of Clinical Oncology · 2024
  34. A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia.Journal of Clinical Oncology · 2024
  35. Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.Journal of Clinical Oncology · 2024
  36. A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.Journal of Clinical Oncology · 2024
  37. Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF).Journal of Clinical Oncology · 2024
  38. Interim safety and efficacy of BP1001 in a phase II acute myeloid leukemia (AML) study.Journal of Clinical Oncology · 2024
  39. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.Journal of Clinical Oncology · 2024
  40. A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure.Journal of Clinical Oncology · 2024
  41. Outcomes of patients with bone marrow fibrosis in de novo and secondary acute myeloid leukemia.Journal of Clinical Oncology · 2024
  42. A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).Journal of Clinical Oncology · 2024
  43. Impact of JAK2 allele burden on MF outcome in the era of ruxolitinib.Journal of Clinical Oncology · 2024
  44. Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.Journal of Clinical Oncology · 2024
  45. Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.Journal of Clinical Oncology · 2024
  46. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationCancer · 2024
  47. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure SyndromesNEJM Evidence · 2024
  48. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phaseCancer · 2024
  49. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemiaCell Reports Medicine · 2024
  50. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2024